Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733455 · ClinicalTrials.gov registry record · Phase 1
Effect of Alpelisib in Healthy Volunteers
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT05733455 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 23 participants.
The verdict
NCT05733455, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers. The main questions it aims to answer are the impact of acute alpelisib-induced insulin resistance on parameters of glucose and lipid metabolism (how healthy people respond to temporary insulin resistance so that the investigators can see what happens to how the liver handles fat and sugar). Participants will: * Consume their total calculated daily caloric needs in nutritional supplements, divided in three meals, and otherwise fast for 24 hours * Take a dose of alpelisib 300 mg or placebo at bedtime * Wear a continuous glucose monitor for 72 hours * Participate in an oral glucose tolerance test (OGTT) Researchers will compare blood tests before and during OGTT in participants randomized (like the flip of a coin) to alpelisib versus placebo to see how the drug treatment affects plasma glucose, serum insulin, and serum lipid parameters (triglycerides, free fatty acids, and apolipoprotein B).
Interventions
- DRUG Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)
- DRUG Placebo (microcrystalline cellulose), 2 capsules
- DEVICE FreeStyle Libre Pro
- DIAGNOSTIC_TEST Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- DIETARY_SUPPLEMENT BOOST Plus nutritional beverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-05-09 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733455
The ClinicalTrials.gov registry entry for NCT05733455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg) is the first listed.
NCT05733455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05733455 about?
NCT05733455 is a clinical study titled "Effect of Alpelisib in Healthy Volunteers". The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers. The main questions it aims to answer are the impact of acute alpelisib-induced insulin resistance on parameters of glucose and lipid metabolism (...
What is the current status of trial NCT05733455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2023-05-09. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05733455?
The interventions under investigation include: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg) (DRUG), Placebo (microcrystalline cellulose), 2 capsules (DRUG), FreeStyle Libre Pro (DEVICE), Oral glucose tolerance test (OGTT) with Trutol glucose beverage (DIAGNOSTIC_TEST), BOOST Plus nutritional beverage (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05733455?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.